Drug delivery: An odyssey of 100 years

Current Opinion in Chemical Biology

Volumn 5, Issue 4, 2001, Pages 439-446

  Pillai, Omathanu ^a   Dhanikula, Anand Babu ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; DEXAMPHETAMINE; POLYMER; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; REVIEW;

EID: 0035416127     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00226-X     Document Type: Review

References (60)

1. Our genome unveiled
2. Quovadis biotech? (Part 1)
3. Drug discovery: A historical perspective
4. Role of dissolution studies in controlled release of drug delivery systems
5. Economic aspects of drug delivery
6. Economic aspects of controlled drug delivery
7. Current status of drug delivery technologies and future directions
8. Innovations in drug delivery
9. Concepts and system design for rate controlled drug delivery
10. Drug delivery systems for challenging molecules
11. Oral drug delivery, small intestine and colon
12. Osmotically controlled drug delivery
13. Recent technological advances in oral drug delivery
14. Peroral route: An opportunity for protein and peptide delivery
15. The role of sorption promoters in increasing the bioavailability of drugs in oral preparations
16. Advances in oral delivery of proteins
17. The development of delivery agents that facilitate the oral absorption of macromolecular drugs
18. Innovations in oral gene delivery
19. Transdermal drug delivery: Overcoming the skin's barrier function
20. Non-invasive delivery of peptides and proteins through skin
21. Transdermal iontophoresis revisited
22. Synergistic effect of enhancers for transdermal drug delivery
23. Intranasal vaccines: Forthcoming challenges
24. Vaccinology - The challenges for non-injected approaches
25. The ascent of pulmonary drug delivery
26. Strategies for particle design using supercritical fluid technologies
27. Latest advances in the development of dry powder inhalers
28. Microchips as controlled drug delivery devices
29. The importance of drug delivery in tissue engineering
30. Emerging protein delivery methods
31. Targeted delivery of antibiotics using liposomes and nanoparticles: Research and applications
32. Polymer conjugates for tumor targeting and intarcytoplasmic delivery. The EPR effect as a common gateway?
33. Monoclonal antibody drug conjugates in the treatment of cancer
34. Localized paclitaxel delivery
35. Drugs with a magnetic attraction to tumors
36. Central nervous system - Drug delivery to treat
37. Cell-penetrating peptides
38. Chemical approaches to drug delivery
39. Gene therapy: The first decade
40. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems
41. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy
42. Transdermal delivery of peptide and proteins
43. Future challenges for drug delivery
44. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
45. Modern bioavailability, bioequivalence and biopharmaceutics, classification system, new scientific approaches to international regulatory standards
46. Biopharmaceutics and pharmacokinetics in drug research
47. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
48. Drug delivery strategies for the new millennium
49. Cell cultures as tools in biopharmacy
50. Applications of immobilized stationary phase liquid chromatography: A potential in vitro technique
51. Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by intestinal epithelium
52. Development of new engineering based capsule for human drug absorption studies
53. Quantitative structure-property relationships in pharmaceutical research - Part I
54. Quantitative structure-property relationships in pharmaceutical research - Part II
55. The biopharmaceutics classification system (BCS): Class III drugs - Better candidates for BA/BE waiver?
56. Evolution of the biopharmaceutics classification system (BCS) to oral modified release (MR) formulations. What do we need to consider?
57. Unconventional dissolution methodologies
58. Oral drug delivery technology: Addressing the solubility/permeability paradigm
59. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum
60. How to survive in tomorrow's healthcare market